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Abstract
A large proportion of older adults are affected by impaired glucose metabolism. Previous studies with fish protein have reported improved glucose regu-
lation in healthy adults, but the evidence in older adults is limited. Therefore, we wanted to assess the effect of increasing doses of a cod protein hydrolysate
(CPH) on postprandial glucose metabolism in older adults. The study was a double-blind cross-over trial. Participants received four different doses (10, 20,
30 or 40 mg/kg body weight (BW)) of CPH daily for 1 week with 1-week washout periods in between. The primary outcome was postprandial response in
glucose metabolism, measured by samples of serum glucose and insulin in 20 min intervals for 120 min. The secondary outcome was postprandial response
in plasma glucagon-like peptide 1 (GLP-1). Thirty-one subjects aged 60–78 years were included in the study. In a mixed-model statistical analysis, no dif-
ferences in estimated maximum value of glucose, insulin or GLP-1 were observed when comparing the lowest dose of CPH (10 mg/kg BW) with the
higher doses (20, 30 or 40 mg/kg BW). The estimated maximum value of glucose was on average 0·28 mmol/l lower when the participants were
given 40 mg/kg BW CPH compared with 10 mg/kg BW (P = 0·13). The estimated maximum value of insulin was on average 5·14 mIU/l lower with
40 mg/kg BW of CPH compared with 10 mg/kg BW (P= 0·20). Our findings suggest that serum glucose and insulin levels tend to decrease with increas-
ing amounts of CPH. Due to preliminary findings, the results require further investigation.
Keywords: Fish protein: Cod protein: Marine peptides: Marine protein hydrolysate: Glucose homeostasis
The human body is dependent on a tight regulation of blood
glucose levels to ensure normal function(1). Blood glucose
levels are regulated within a narrow range, and glucose homeo-
stasis is maintained through an intricate network of hormones
and neuropeptides that are released in the body(1,2). With
increasing age, glucose metabolism changes and a large pro-
portion of older adults are affected by impaired glucose
metabolism(3,4). Since skeletal muscle is the major site for
insulin-stimulated uptake of glucose(5,6), it has been suggested
that low skeletal muscle mass observed in some older adults
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with reduced muscle mass and function might result in
reduced capacity for glucose disposal(7). Furthermore, higher
fasting and postprandial values of glucose and insulin have
been associated with lower muscle mass in older adults(8).
The gradual decline in muscle mass and function observed
with increasing age(9–11) is a major threat to healthy ageing,
and causes reduced mobility, increased disability, loss of inde-
pendence and overall reduced quality of life(12,13).
Several previous intervention studies have reported
improved insulin sensitivity(14,15) and glucose tolerance(14,16)
in humans and rodents after supplementation with fish pro-
tein. Furthermore, 3-month supplementation with a daily
dose of 1·4 g protein hydrolysate from blue whiting given to
overweight adults increased blood concentrations of glucagon-
like peptide 1 (GLP-1). No further effects were observed when
the participants were given a higher dose of 2·8 g, which might
indicate a plateau effect starting at 1·4 g(17). GLP-1 is released
from the enteroendocrine L-cells in response to food intake
and lowers blood glucose levels by stimulating insulin secre-
tion, suppressing glucagon secretion and slowing gastric
emptying(18). In general, fish protein and hydrolysates from
fish protein have a well-balanced distribution of amino acids
and should be considered a high-quality protein source, and
there is an increasing amount of evidence supporting a favour-
able effect of these proteins on metabolic health(19).
The evidence of health effects of cod protein as a nutritional
supplement is limited, and only a few studies in healthy and
overweight adults have been conducted. A recent study
reported that an 8-week supplementation with 6 g of residual
material from cod (press-cake meal) in a group of overweight
or obese adults resulted in decreased postprandial concentra-
tions of serum NEFA, which might indicate an effect on mar-
kers for glucose regulation(20). In addition, a small pilot study in
overweight adults observed improved glucose regulation after
daily supplementation with 2·5 g of protein from cod for 8
weeks(21). No changes in insulin, insulin C-peptide or NEFA
in serum were observed(21). Furthermore, we recently demon-
strated that supplementation with a single dose of 20 mg/kg
body weight (BW) of a protein hydrolysate from cod, given
before a breakfast meal, reduced postprandial insulin secretion
in forty-one healthy adults between 41 and 64 years, when com-
pared with control(22). We did not observe any effects on post-
prandial blood glucose response or on the levels of GLP-1.
Based on current knowledge, it is of interest to further
explore potential favourable effects of cod protein on para-
meters closely related to muscle health, including parameters
of glucose metabolism in an older population. To our knowl-
edge, no previous trial has evaluated the effect of increasing
doses of a supplement with cod protein hydrolysate (CPH)
on glucose metabolism in older adults. Therefore, the aim of
the present study was to investigate the effect of supplementa-
tion with four different weight-adjusted doses of a CPH on
postprandial glucose regulation in a group of older adults
aged 60–80 years. Based on the results from the study, we
hoped to create a basis for selecting an effective daily dose
of CPH for further use in clinical study protocols in patient
groups with muscle health issues, inflammatory conditions
or abnormal glucose metabolism.
Experimental methods
Study design
The study was a double-blind cross-over trial. The participants
received four different doses (10, 20, 30 or 40 mg/kg BW) of
CPH daily for 1 week with 1-week washout periods in between
the dose intervals. Each participant received all four different
dose intervals in random order. The participants were
instructed to take the supplement each morning before break-
fast for 7 d. After an initial screening visit, included partici-
pants came to the research unit on four different occasions,
separated by 2 weeks. In total, the study lasted for 7 weeks.
The primary outcome was postprandial response in glucose
metabolism, measured by venous samples of glucose and insu-
lin. Secondary outcomes were plasma GLP-1 and adverse
effects measured by symptom questionnaires.
The study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures involv-
ing human subjects were approved by the Regional Committee
for Medical and Health Research Ethics of Central Norway
(2017/1795). Written informed consent was obtained from
all subjects. The trial is registered at www.clinicaltrials.gov as
NCT03526744.
Participants
Participants were recruited by advertisement on the external
websites and on notice boards at Haukeland University
Hospital, Bergen and Ålesund Hospital, Ålesund.
Recruitment took place between March and July 2018, and
the study was conducted between April and November of
the same year.
Potential participants were screened for general eligibility by
telephone, and suitable candidates were invited for a baseline
evaluation visit, with further information and baseline blood
chemistry. The criteria for inclusion were age between 60
and 80 years, BMI between 20 and 30 kg/m2 and signed
informed consent. Criteria for exclusion were allergy and intol-
erances to fish and/or shellfish, pharmacologically treated dia-
betes mellitus, low or unstable blood pressure, chronic
diseases or medication that were likely to interfere with the
evaluation of the study endpoints, acute infections, substance
misuse (excessive alcohol consumption and/or narcotic sub-
stances assessed by physician) or unwillingness to comply
with the requirements of the study. The participants were
instructed to not take any nutritional supplements containing
n-3 PUFA for 2 weeks before study commencement and dur-
ing the course of the study.
Study protocol
The participants came to the research unit on five different
occasions, including a screening visit. Before inclusion, the
subjects underwent clinical examination by a physician, base-
line biochemistry and measurement of height, weight and
blood pressure.
A 3-d prospective diet diary was recorded prior to starting

























































































































level of physical activity was assessed at baseline and at the end
of the study by asking the participants two questions regarding
moderate physical activity and vigorous activity (self-reported).
The participants were instructed not to change diet habits or
the level of physical activity during the study period.
The study consisted of four different intervention cycles.
Before each intervention cycle, the participants received six
bottles containing powder with CPH, labelled 1 to 6. We
instructed the participants to take one bottle each morning
during the intervention cycle. On days of study tests, day 7
in each intervention cycle, the participants came to the
research facility in a fasting condition between 08.00 and
09.00 hours. After baseline blood sampling, we gave the last
dosage of CPH followed by a standardised breakfast meal
10 min later. At 25 min after the CPH drink was served and
15 min after the breakfast meal had started, we took the
first postprandial blood sample (0 min sample). Thereafter,
the participants spent 2 h in the vicinity of the research unit
to allow for repeated sampling of blood, at 20 min intervals
until 120 min.
The standardised breakfast meal consisted of two slices of
semi-coarse bread (50 % whole wheat, 80 g bread), 10 g mar-
garine, 20 g strawberry jam and 20 g white cheese, providing a
total of 1485 kJ (355 kcal), 41 g carbohydrate, 12·5 g protein
and 15 g fat. The drink contained 22·5 g carbohydrate and
approximately 418 kJ (100 kcal), and including the drink, the
breakfast provided in total 1900 kJ (455 kcal). The amount
of energy and carbohydrates in the breakfast was calculated
to induce an adequate blood glucose response. No coffee or
tea was served, but water was given ad libitum.
We handed out the six bottles for the next intervention cycle
at the end of the test day and gave instructions for when to
start the next intervention cycle. Between intervention cycles,
the participants had a washout period of 7 d. All participants
received a text message on the morning of the day they
were to start the next intervention cycle.
Assessments
At the screening visit we assessed the participant’s medical his-
tory and measured biochemical parameters for nutritional sta-
tus (albumin, prealbumin, vitamins B12 and D). We measured
biochemical safety parameters at the screening visit and the
end of study visit.
During the test days, baseline fasting serum glucose and
serum insulin were measured 25 min before the first postpran-
dial blood sample (time (t) = 0 min postprandial).
Subsequently, serum glucose and insulin were measured
every 20 min for 2 h (t = 20, 40, 60, 80, 100 and 120 min post-
prandial). Baseline GLP-1 was measured and thereafter post-
prandially at t = 0, 20, 40, 80 and 120 min. Blood pressure
was measured at three time points during the test day as a
safety parameter (t = 0, 40 and 120 min).
Two questionnaires evaluating the participants’ symptoms
were used to identify possible adverse events during each
intervention period and on study visits. In each intervention
period, a visual analogue scale was filled out before the parti-
cipants took the first dose with CPH on day 1 and before the
last dose on day 7. Further, a questionnaire validated for the
evaluation of gastrointestinal symptoms(23) was filled out 2 h
after intake of CPH on day 1 and day 7 (end of test day,
t = 120 min).
Test material
The protein hydrolysate powder was delivered from the manu-
facturer (Firmenich Bjørge Biomarin AS) in neutral bottles
coded with participant number and dose level (1–4). The bot-
tles were coded by a person not involved in the performance
of the study and the different dose levels were randomly allo-
cated to the participants according to a central digital random-
isation list. Study participants and investigators were blinded to
the dose content in the bottles (double-blinded study). The key
of randomisation was provided to the investigators when the
trial had ended, and the statistical analysis was completed.
The powder contained 4 % protein (CPH raw material) and
96 % carbohydrate (maltodextrin) and was flavoured with
lemon. The CPH raw material contained approximately 89
% protein by weight, <0·2 % fat, 0 % carbohydrate, <3·0 %
water, 10 % ash, 0·1 % NaCl, 1·7 % Na and 0·07 % chloride.
The amino acid composition of CPH raw material is presented
in Table 1. The hydrolysation process has been presented in a
previous publication(22).
Estimation of energy intake
Calculations of energy and macronutrient intake were per-
formed using Kostholdsplanleggeren (Norwegian Food Safety
Authority and The Norwegian Directorate of Health, Oslo,
Norway)(24), based on the reported food and drink intake
data from the participants at baseline and at the end of the
study. Participants registered their intake of food and drink
Table 1. Amino acid and taurine composition of the cod protein
hydrolysate used in the present study















































































































































for three consecutive days, preferably including one weekend
day, prior to the first dose and at the end of the study. The
dietary records were used to record the participants’ diet pat-
terns and to assess whether the participants made changes to
their diets during the study period.
Analyses of blood samples
Baseline biochemistry was analysed according to standard
accredited methods at the Laboratory for Clinical
Biochemistry, Haukeland University Hospital (Bergen,
Norway) and the Department of Medical Biochemistry,
Ålesund Hospital (Ålesund, Norway).
Glucose and insulin were measured in serum according to
standard accredited methods at the Laboratory for Clinical
Biochemistry, Haukeland University Hospital (Bergen,
Norway). Serum was obtained by centrifugation of full
blood at 2000 g at room temperature (20°C) for 10 min
after 30–60 min of coagulation, using serum separator cloth
activator tubes. Samples were aliquoted and stored at −80°C
prior to analysis.
Plasma for the determination of GLP-1 was obtained by
centrifugation of EDTA full blood at 1800 g at −4°C for
10 min, within 20 min after blood sampling. Prior to sampling,
to EDTA blood sampling tubes were added 10 µl dipeptidyl
peptidase-4 inhibitor (DPP4-010; DRG Diagnostics) per ml
EDTA blood. GLP-1 plasma was aliquoted and stored at
−80°C prior to analysis. The GLP-1 analyses were performed
using an ELISA kit from IBL International GmbH (GLP-1
(7–36) active ELISA, reference RE53121).
Statistical analysis
Statistical analyses were performed using Stata v15.1
(StataCorp LLC) and SPSS software (IBM SPSS Statistics
24). Graphical work was conducted in GraphPad Prism ver-
sion 7.0 (GraphPad Software, Inc.). Data are presented as
means and standard deviations for continuous variables, and
frequencies and relative frequencies for categorical variables.
To estimate the effect of dose we calculated the maximum
observed value and the AUC for the time course of each
outcome variable, for each combination of person and dose.
We then fitted mixed models with the outcome measure
(maximum value or AUC) as the dependent variable, fixed
effects of dose and random intercepts across persons.
Carry-over effects were assessed using a standard
likelihood-ratio test to test for interaction between dose and
ordering. Paired-samples t tests were used to compare changes
in energy intake and macronutrient intake from baseline to the
end of the study. P values <0·05 were considered statistically
significant.
The sample size was not feasible to calculate for power ana-
lysis, due to lack of similar studies. Possible health effects of
supplementation with residual material from cod as protein
hydrolysate has previously not been studied in a group of
older adults, and therefore we had no basis for calculating




From April to June 2018 we screened fifty-one subjects for
study participation and thirty-three were enrolled in the
study (Fig. 1). Two of the included participants were excluded
before the first test day due to difficulties with blood sampling.
Overall, thirty-one subjects aged 60–78 years completed the
trial (thirteen males and eighteen females). One participant
had to be excluded on the final study day due to difficulties
with blood sampling; therefore data on glucose, insulin and
GLP-1 are only available for three of the dose levels. Four
of the participants were excluded from the final statistical ana-
lysis of GLP-1 due to analytical errors. Baseline characteristics
of the participants are presented in Table 2.
Energy and macronutrient intake
No statistically significant differences were observed in energy
intake or macronutrient intake during the course of the study
(Table 3). One participant did not fill out the 3-d food record
at the end of the study. Based on the reported intake of protein
from the food diaries at baseline and at the end of the study,
an average intake of 1·2 g protein/kg BW at baseline was esti-
mated and this did not change during the study period (P =
0·36; estimated average intake at end of study 1·1 g protein/
kg BW).
Postprandial measurements
In a mixed-model analysis, no statistically significant differ-
ences in estimated maximum value of glucose, insulin or
GLP-1 were observed when comparing the lowest dose of
10 mg/kg BW of CPH with 20, 30 or 40 mg/kg BW
(Table 4). The estimated maximum value of glucose was on
average 0·28 mmol/l lower when the participants were given
the highest dose of 40 mg/kg BW CPH compared with the
lowest dose of 10 mg/kg BW (P = 0·13). The estimated
maximum value of insulin was on average 5·14 mIU/l lower
after participants were given the highest dose of 40 mg/kg
BW of CPH compared with the lowest dose of 10 mg/kg
BW (P = 0·20). The estimated maximum value of GLP-1
was on average 0·34 pmol/l lower when given the highest
dose (40 mg/kg BW) compared with the lowest dose of
CPH (10 mg/kg BW) (P= 0·48). No carry-over effect was
observed for glucose (P= 0·19), insulin (P = 0·21) or GLP-1
(P = 0·08).
No statistically significant differences in AUC between the
four different doses were observed for any of the outcome
measures when comparing the lowest dose of 10 mg/kg BW
of CPH with the higher doses of 20, 30 or 40 mg/kg BW.
For glucose, AUC was calculated from t = baseline until
t = 80, excluding t = 100 and t = 120 (Fig. 2), based on the
assumption that for the majority of individuals, glucose levels
had returned to their baseline levels. The AUC for glucose was
on average 1·16 mmol/l × min higher when given 20 mg/kg
BW of CPH (P = 0·14), on average 0·27 mmol/l × min higher
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screening visit (n 12)
Fig. 1. Flowchart depicting the inclusion and randomisation process. BW, body weight.
Table 2. Baseline characteristics of the thirty-one participants





Age (years) 67·8 4·9
Weight (kg) 76·6 11·3
BMI (kg/m2) 26·0 2·6
Systolic BP (mmHg) 137 15
Diastolic BP (mmHg) 82 10
HbA1c (mmol/mol) 36·7 4·3
Fasting glucose (mmol/l) 5·4 0·6
BP, blood pressure; HbA1c, glycated Hb.
Table 3. Dietary intake at baseline and at the end of the study*
(Mean values and standard deviations)
Baseline End of study
P†Mean SD Mean SD
Energy intake (kJ) 7765 1586 7807 1506 0·84
Protein (g) 86·9 20·6 84·2 18·1 0·32
Fat (g) 73·1 19·3 75·2 18·6 0·50
Carbohydrates (g) 215·2 65·4 213·8 55·8 0·95
* Food and drink intakes were registered for 3 d at baseline and at the end of the
study.
†Paired-samples t tests were used to compare changes in energy intake and
macronutrient intake from baseline to the end of the study. No significant differences

























































































































mmol/l × min lower when given 40 mg/kg BW (P= 0·32),
when compared with the lowest dose of 10 mg/kg BW of
CPH. If all measuring points were included in the statistical ana-
lysis of glucose, also including t = 100 and t = 120, the
significance of the results did not change (Fig. 2). For insulin,
the AUC was on average 11·3 mIU/l × min higher
when given 20 mg/kg BW of CPH (P = 0·49), on average
6·84 mIU/l × min higher when given 30 mg/kg BW of CPH
(P= 0·67) and on average 7·4 mIU/l × min lower when given
40 mg/kg BW (P = 0·65), when compared with the lowest
dose of 10 mg/kg BW of CPH. For GLP-1, the AUC was on
average 1·38 pmol/l × min lower when given 20 mg/kg BW
of CPH (P = 0·36), on average 0·01 pmol/l × min lower
when given 30 mg/kw BW of CPH (P = 0·99) and on average
1·09 pmol/l × min lower when given 40 mg/kg BW of CPH
(P= 0·47), when compared with the lowest dose of 10 mg/kg
BW of CPH. A graphical representation of the metabolic
response for serum glucose, serum insulin and plasma GLP-1
concentration on the test day, the last day in the four different
intervention cycles, is presented in Fig. 2. A bar chart showing
total AUC for serum glucose, serum insulin and plasma GLP-1
is presented in Fig. 3.
Adverse effects
No adverse effects were reported in the questionnaires, from
the biochemical safety parameters or from the biochemical
parameters for nutritional status.
Discussion
The overall objective of the present study was to evaluate the
effect of increasing doses of a supplement with CPH on glu-
cose metabolism in older adults, aiming to find a dose
response and creating a basis for an optimal daily dose for
future clinical use. We investigated the effect on postprandial
glucose regulation of four different doses of a CPH supple-
ment (10, 20, 30 and 40 mg/kg BW) taken daily for 1 week.
Although no statistically significant differences were observed
between the postprandial measurements after the four differ-
ent doses, our results indicate that the highest dose of CPH
(40 mg/kg BW), equal to 3·2 g/d in an individual with a
BW of 80 kg, is the most efficient in lowering postprandial
blood glucose levels and insulin concentrations, when com-
pared with the lower doses (10, 20 and 30 mg/kg BW).
In a previous publication, we reported that a single dose of
20 mg/kg BW CPH significantly reduced postprandial insulin
concentrations in healthy, middle-aged to older individuals,
without affecting postprandial glucose levels or GLP-1 levels,
compared with control (casein)(22). We hypothesised that the
CPH might enhance the insulin sensitivity and affect other
mechanism involved in blood glucose uptake in peripheral tis-
sue. The significantly lower insulin concentration after intake
of CPH may be of more interest in patients with reduced insu-
lin sensitivity.
To our knowledge, only one small pilot study has been con-
ducted with fish protein hydrolysate in an older population(25).
In this double-blind, randomised controlled study, a daily diet-
ary supplement of 5·2 g fish protein hydrolysate from blue
whiting, or placebo, was given to twenty-four nursing home
residents daily for 6 weeks. No differences in serum concen-
trations of glucose or insulin after 6-week supplementation
with fish protein were observed, when compared with pla-
cebo(25). However, since this was a study population with
Table 4. Estimated maximum values of glucose, insulin and glucagon-
like peptide 1 (GLP-1) derived from a mixed model





difference 95 % CI P
Glucose (mmol/l) 10 0 (Reference)
20 0·33 −0·04, 0·70 0·08
30 0·09 −0·29, 0·46 0·65
40 −0·28 −0·65, 0·08 0·13
Insulin (mIU/l) 10 0 (Reference)
20 3·59 −4·34, 11·5 0·38
30 3·42 −4·60, 11·4 0·40
40 −5·14 −13·1, 2·79 0·20
GLP-1 (pmol/l) 10 0 (Reference)
20 −0·66 −1·59, 0·28 0·17
30 −0·11 −1·06, 0·84 0·83
40 −0·34 −1·28, 0·59 0·48
BW, body weight.
Fig. 2. Metabolic responses for serum glucose (a), serum insulin (b) and plasma glucagon-like peptide 1 (GLP-1) (c) concentrations after intake of a standardised
breakfast meal and the last dosage of the cod protein hydrolysate (CPH). Dose levels were 10, 20, 30 and 40 mg/kg body weight (BW). Results for serum glucose
and insulin are presented for all thirty-one subjects, whereas for GLP-1 the results are presented for twenty-seven subjects (four participants were excluded from the
statistical analysis due to analytical errors). Values are means. Time point 0 min is the first postprandial blood sample, taken 25 min after the drink was served and 15

























































































































older adults who lived in a nursing home setting, the results are
not directly transferable to our study population with home-
dwelling older adults.
Based on a few previous studies investigating the effect of
supplements containing protein hydrolysates from fish on
metabolic health(17,26), we hypothesised that small doses of
CPH may be effective due to the content of small, easily
absorbable bioactive peptides. These are capable of rapidly
affecting different metabolic pathways involved in glucose
regulation and hence leading to a more rapid glucose response
in the body. Thus, we presume that a potential observed effect
on postprandial glucose metabolism can be attributed to the
content of small, bioactive peptides in the supplement, and
not the protein intake per se, which is negligible compared
with overall protein content in a normal meal. Previous studies
investigating supplements with fish protein or hydrolysates of
fish proteins have reported doses in the range of 1 to 6 g per d
to beneficially influence blood glucose metabolism when com-
pared with control(16,17,21,26).
The results have to be interpreted taking certain limitations
in the design into account. The use of a cross-over design
always implies a risk of a carry-over-effect. According to ana-
lysis of all possible interaction effects between doses and time
periods, the results in this cross-over trial are not biased by a
carry-over effect. We included a washout period of 7 d
between each week of peptide supplementation. We presume
1 week to be a sufficient washout period, as dietary protein
in general has a high turnover rate and the investigated
doses of protein hydrolysate were low(27). On study days, the
supplement was given to the participants 10 min before break-
fast and 25 min before the first postprandial blood sample was
taken. This design might have caused a metabolic response
even before the breakfast was served. As a result, we may
have missed some early information on postprandial glucose
response. Furthermore, a 2-week washout period for the use
of supplements containing n-3 PUFA before starting on the
first dose of CPH may not have been enough and a longer
washout period could arguably have strengthened the design.
It is possible that the short supplementation period of 1
week could have affected the results, and that a longer period
would have been preferable. However, we have previously
observed an effect after only one acute supplementation (20
mg/kg BW) in healthy middle-aged adults(22). A longer inter-
vention period would have made it more challenging to
include participants and avoid drop-outs, due to a long time-
frame of the study. Therefore, due to practical implementa-
tions of the study, 1 week of supplementation (7 d) for each
dose was chosen. Finally, the design could have been strength-
ened by including a postprandial blood sampling at day 0 for
each intervention cycle or a control group (0 mg/kg BW
CPH). However the study was performed based on a previous
study, where we report that a low dose of CPH (20 mg/kg
BW) significantly reduced the postprandial insulin concentra-
tion(22), and we therefore aimed to further evaluate the effect
of different doses in the present study. An additional study day
in each intervention period would also have made it more
challenging to include participants and avoid a high drop-out
rate, and would be difficult to implement due to limited
resources. Based on this, we chose to only include postpran-
dial blood sampling at the end of each intervention period.
To our knowledge, no previous publication has reported on
the metabolic effect of different low doses of fish protein
hydrolysate in an older adult population. Although no signifi-
cant differences were observed in this trial, our findings sug-
gest that low doses of fish protein hydrolysate might be
effective and capable of improving blood glucose regulation
in older adults. According to our findings, further studies
investigating effects of supplements containing hydrolysates
of fish proteins should be able to observe a metabolic effect
from doses starting around 40 mg/kg BW, equal to 3·2 g
per d in an individual with a BW of 80 kg. Based on this,
we suggest that a dose ranging from 3 to 4 g per d is a reason-
able starting point for future clinical studies. Due to prelimin-
ary findings, these results require further investigation.
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